Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Open accessThe DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Abstract
Is cancer immunotherapy a private affair?: Immune checkpoint blockade, a relatively new cancer treatment, substantially extends the survival of a subset of patients. Previous work has shown that patients whose tumors harbor the largest number of mutations—and thus produce a large number of “neoantigens” recognized as foreign by the immune system—are most likely to benefit. Expanding on these earlier studies, Van Allen et al. studied over 100 patients with melanoma and found a similar correlation (see the Perspective by Gubin and Schreiber). There was no evidence, however, that specific neoantigen sequences were shared by patients who responded. Science , this issue p. 207 , see also p. 158
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“ORR and Kaplan-Meier survival analysis revealed that the PathTIGR model effectively stratified patients with melanoma into subgroups exhibiting significantly disparate therapeutic responses (Fisher’s exact test, P < 0.0001; Fig. 4C) and clinical outcomes (log-rank test, P < 0.0001; Fig. 4, D and E).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“The model achieved AUCs of 0.734, 0.729, and 0.935 at 1, 2, and 3 years, respectively (Fig. 4F).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“Cox proportional hazard regression analysis established the algorithm’s independence as a prognostic determinant following adjustment for conventional clinicopathological covariates (P < 0.001; Fig. 4G and table S1).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
In the citing paper
“it achieved an AUC of 0.989, an AUPRC of 0.993, an F1 score of 0.99, and a C-index of 0.989 (Fig. 4, A and B, and fig. S2A).”
From PathTIGR: A pathway topology-informed graph representation learning framework for immunotherapy response prediction (2026) · doi:10.1126/sciadv.aed6373 · cites this paper as [37]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534 · cited 2×
“To stratify our cohort, “clinical benefit” was defined using a composite end point of complete response or partial response to ipilimumab by RECIST criteria (21) or stable disease by RECIST criteria with overall survival greater than 1 year (n = 27).”
Robinson, J. T., Thorvaldsdóttir, H., Winckler, W., Guttman, M., Lander, E. S., Getz, G., & Mesirov, J. P. (2011) · Nature Biotechnology · doi:10.1038/nbt.1754 · Cited by 15,390
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
Self-citationPD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Self-citationMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples
Cibulskis, K., Lawrence, M. S., Carter, S. L., Sivachenko, A., Jaffe, D., Sougnez, C., Gabriel, S., Meyerson, M., Lander, E. S., & Getz, G. (2013) · Nature Biotechnology · doi:10.1038/nbt.2514 · Cited by 4,981 · cited 1×
“We performed somatic mutation identification (table S1) and germline human lymphocyte antigen (HLA) typing (table S2) using established methods (14, 19).”
Self-citationThe future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878 · cited 1×
“Incorporation of patient-matched RNA-level information may help prioritize putative neoantigens and elucidate possible tumor immune microenvironmental effects, including interferon-related genes and additional immune checkpoint molecules that are relevant in melanoma (28).”
Cited by
Items 401–500 of 1,010
Hu, C., He, X., Chen, Y., Yang, X., Qin, L., Lei, T., Zhou, Y., Gong, T., Huang, Y., & Gao, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202007149 · Cited by 139
Lussier, D. M., Alspach, E., Ward, J. P., Miceli, A. P., Runci, D., White, J. M., Mpoy, C., Arthur, C. D., Kohlmiller, H. N., Jacks, T., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102611118 · Cited by 152
Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines
Martin, S. D., Brown, S. D., Wick, D. A., Nielsen, J. S., Kroeger, D. R., Twumasi-Boateng, K., Holt, R. A., & Nelson, B. H. (2016) · PLOS ONE · doi:10.1371/journal.pone.0155189 · Cited by 137
“Clinical responses to anti-PD-1[3] and -CTLA-4[4,5] antibodies have been associated with high mutation load, suggesting that neoantigens may be the most relevant target antigens underlying successful immune checkpoint blockade.”
BackgroundThe Oncopig Cancer Model: An Innovative Large Animal Translational Oncology Platform
Schachtschneider, K. M., Schwind, R. M., Newson, J. L., Kinachtchouk, N., Rizko, M., Mendoza-Elias, N., Grippo, P. J., Principe, D. R., Park, A. J., Overgaard, N. H., et al. (2017) · Frontiers in Oncology · doi:10.3389/fonc.2017.00190 · Cited by 150
Genomic landscape associated with potential response to anti-CTLA-4 treatment in cancers
Ock, C.-Y., Hwang, J.-E., Keam, B., Kim, S.-B., Shim, J.-J., Jang, H.-J., Park, S., Sohn, B. H., Cha, M., Ajani, J. A., et al. (2017) · Nature Communications · doi:10.1038/s41467-017-01018-0 · Cited by 138
Immunogenomics Analysis Reveals that TP53 Mutations Inhibit Tumor Immunity in Gastric Cancer
Jiang, Z., Liu, Z., Li, M., Chen, C., & Wang, X. (2018) · Translational Oncology · doi:10.1016/j.tranon.2018.07.012 · Cited by 119
A secreted PD-L1 splice variant that covalently dimerizes and mediates immunosuppression
Mahoney, K. M., Shukla, S. A., Patsoukis, N., Chaudhri, A., Browne, E. P., Arazi, A., Eisenhaure, T., Pendergraft, W. F., Hua, P., Pham, H. C., et al. (2018) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-018-2282-1 · Cited by 144
“Transcriptomic databases Expression levels of full-length PD-L1 and secPD-L1 were analyzed in publicly available tumor specimens from The Cancer Cell Line Encyclopedia (CCLE), The Cancer Genome Atlas (TCGA), normal tissue specimens prepared from autopsy [Genotype-Tissue Expression (GTEx) database], melanoma specimens…”
MethodSelf-citationLyu, H., Li, M., Jiang, Z., Liu, Z., & Wang, X. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.07.009 · Cited by 111
Wu, Y., Xu, J., Du, C., Wu, Y., Xia, D., Lv, W., & Hu, J. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.01161 · Cited by 139
Long, H., Jia, Q., Wang, L., Fang, W., Wang, Z., Jiang, T., Zhou, F., Zheng, J., Huang, J., Zhou, L., et al. (2022) · Cancer Cell · doi:10.1016/j.ccell.2022.04.018 · Cited by 152
Colli, L. M., Machiela, M. J., Myers, T. A., Jessop, L., Yu, K., & Chanock, S. J. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0170 · Cited by 137
“4 synonymous mutations correlates with a response to checkpoint inhibitors in melanoma (15,16) and NSCLC (17).”
BackgroundNF 1‐mutated melanoma tumors harbor distinct clinical and biological characteristics
Cirenajwis, H., Lauss, M., Ekedahl, H., Törngren, T., Kvist, A., Saal, L. H., Olsson, H. L., Staaf, J., Carneiro, A., Ingvar, C., et al. (2017) · Molecular Oncology · doi:10.1002/1878-0261.12050 · Cited by 156
“In particular, tumors with high mutational burden (or deficiency in the DNA mismatch repair pathway leading to such an increase) have recently been shown to respond better to immune checkpoint blockade agents (Le et al., 2015; McGranahan et al., 2016; Rizvi et al., 2015; Van Allen et al., 2015).”
BackgroundDeterminants for Neoantigen Identification
Garcia-Garijo, A., Fajardo, C. A., & Gros, A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01392 · Cited by 137
Layer, J. P., Kronmüller, M., Quast, T., Konijnenberg, D., Effern, M., Hinze, D., Althoff, K., Schramm, A. R., Westermann, F., Peifer, M., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1320626 · Cited by 147
“inhibitors, because it correlates with the number of neoantigens.(9,14,26) In lung cancer, a recent study identified a nonsynon-”
BackgroundBassani-Sternberg, M., & Gfeller, D. (2016) · The Journal of Immunology · doi:10.4049/jimmunol.1600808 · Cited by 134
Immune checkpoint blockade therapy
Wieder, T., Eigentler, T., Brenner, E., & Röcken, M. (2018) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2018.02.042 · Cited by 150
Zhang, Z., Chen, L., Chen, H., Zhao, J., Li, K., Sun, J., & Zhou, M. (2022) · EBioMedicine · doi:10.1016/j.ebiom.2022.104207 · Cited by 160
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
“However, T-cell exclusion in tumors presents a significant factor for the adverse outcome of cancer patients and the resistance to cancer immunotherapies (1, 2).”
BackgroundRNA-SeQC 2: efficient RNA-seq quality control and quantification for large cohorts
Graubert, A., Aguet, F., Ravi, A., Ardlie, K. G., & Getz, G. (2021) · Bioinformatics · doi:10.1093/bioinformatics/btab135 · Cited by 131
Hodi, F. S., Wolchok, J. D., Schadendorf, D., Larkin, J., Long, G. V., Qian, X., Saci, A., Young, T. C., Srinivasan, S., Chang, H., et al. (2021) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-20-0983 · Cited by 153
“In advanced melanoma, high TMB is associated with response in patients receiving IPI (1, 19), NIVO followed by IPI (20), and NIVO in IPI-naive patients (21).”
Self-citationThe landscape of T cell antigens for cancer immunotherapy
Peri, A., Salomon, N., Wolf, Y., Kreiter, S., Diken, M., & Samuels, Y. (2023) · Nature Cancer · doi:10.1038/s43018-023-00588-x · Cited by 147
Mechanisms of Resistance to Immune Checkpoint Blockade
Liu, D., Jenkins, R. W., & Sullivan, R. J. (2019) · American Journal of Clinical Dermatology · doi:10.1007/s40257-018-0389-y · Cited by 130
Galsky, M. D., Saci, A., Szabo, P. M., Han, G. C., Grossfeld, G., Collette, S., Siefker-Radtke, A., Necchi, A., & Sharma, P. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4162 · Cited by 131
Federico, L., McGrail, D. J., Bentebibel, S.-E., Haymaker, C., Ravelli, A., Forget, M., Karpinets, T. V., Jiang, P., Reuben, A., Negrao, M. V., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.09.021 · Cited by 146
Yuan, X., Duan, Y., Xiao, Y., Sun, K., Qi, Y., Zhang, Y., Ahmed, Z., Moiani, D., Yao, J., Li, H., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0900 · Cited by 130
Variant classification in precision oncology
Leichsenring, J., Horak, P., Kreutzfeldt, S., Heining, C., Christopoulos, P., Volckmar, A., Neumann, O., Kirchner, M., Ploeger, C., Budczies, J., et al. (2019) · International Journal of Cancer · doi:10.1002/ijc.32358 · Cited by 140
Berghoff, A. S., Ricken, G., Wilhelm, D., Rajky, O., Widhalm, G., Dieckmann, K. U., Birner, P., Bartsch, R., & Preusser, M. (2016) · Journal of Neuro-Oncology · doi:10.1007/s11060-016-2216-8 · Cited by 135
Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives
Krasniqi, E., Barchiesi, G., Pizzuti, L., Mazzotta, M., Venuti, A., Maugeri‐Saccà, M., Sanguineti, G., Massimiani, G., Sergi, D., Carpano, S., et al. (2019) · Journal of Hematology & Oncology · doi:10.1186/s13045-019-0798-2 · Cited by 143
PD‐1/PD‐L1‐dependent immune response in colorectal cancer
Payandeh, Z., Khalili, S., Somi, M. H., Mard‐Soltani, M., Baghbanzadeh, A., Hajiasgharzadeh, K., Samadi, N., & Baradaran, B. (2020) · Journal of Cellular Physiology · doi:10.1002/jcp.29494 · Cited by 137
“…upregulation of PD‐1, PD‐L1, CTLA‐4, and pro‐tumor inflammatory cytokines, which inhibited the therapeutic effect of PD‐1 blockade (Akbay et al., 2013) (Van Allen et al., 2015) Combination with targeting mutant tumor neoantigens Combination of Targeting neoantigens and PD‐1, PD‐L1 The mutant…”
BackgroundRejection of immunogenic tumor clones is limited by clonal fraction
Gejman, R. S., Chang, A. Y., Jones, H. F., DiKun, K., Hakimi, A. A., Schietinger, A., & Scheinberg, D. A. (2018) · eLife · doi:10.7554/elife.41090 · Cited by 126
Applying artificial intelligence for cancer immunotherapy
Xu, Z., Wang, X., Zeng, S., Ren, X., Yan, Y., & Gong, Z. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.02.007 · Cited by 126
“In addition, certain genomic or genetic features, such as PD-L1 expression, deficient DNA mismatch repair, neoantigen load and tumor mutation burden, are also relevant to immunotherapeutic responses that could be further researched and combined in an AI application 49 e 51 .”
BackgroundCytotoxic lymphocytes target characteristic biophysical vulnerabilities in cancer
Tello‐Lafoz, M., Srpan, K., Sanchez, E. E., Hu, J. Y., Remšík, J., Romin, Y., Calò, A., Hoen, D. R., Bhanot, U. K., Morris, L. G. T., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.02.020 · Cited by 135
Strategies to Improve Drug Delivery Across the Blood–Brain Barrier for Glioblastoma
Narsinh, K. H., Perez, E., Haddad, A. F., Young, J. S., Savastano, L. E., Villanueva-Meyer, J. E., Winkler, E. A., & de Groot, J. (2024) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-024-01338-x · Cited by 152
Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma
Yu, C., Liu, X., Yang, J., Zhang, M., Jin, H., Ma, X., & Shi, H. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00990 · Cited by 126
“Previous studies indicated that clinical benefits were significantly associated with neo-antigen load, overall mutational load, and the expression of cytolytic markers in the immune microenvironment (55).”
BackgroundPrickett, T. D., Crystal, J. S., Cohen, C. J., Pasetto, A., Parkhurst, M. R., Gartner, J. J., Yao, X., Wang, R., Gros, A., Li, Y. F., et al. (2016) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-15-0215 · Cited by 126
“Whole-exome sequencing of fresh uncultured tumor and normal cells from patient 3713 initially indicated that this tumor contained over 4,000 nonsynonymous somatic variants, a relatively high mutational load in comparison with the majority of cutaneous melanomas (27), although melanomas that possess similar or higher m…”
ResultWang, P., Chen, Y., & Wang, C. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.672677 · Cited by 156
“It has also been shown that patients with melanoma, who are treated with CTLA4 inhibitors, demonstrated a significant association of TMB, TNB and cytolytic marker expression with clinical benefit (27).”
BackgroundBeyond the Barrier: Unraveling the Mechanisms of Immunotherapy Resistance
Bell, H. N., & Zou, W. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-101819-024752 · Cited by 149
Xue, Y., Lu, F., Chang, Z., Li, J., Gao, Y., Zhou, J., Luo, Y., Lai, Y., Cao, S., Li, X., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40518-0 · Cited by 145
“Similarly, the analysis of another cohort from Cancer-Immu algorithm 50,51 suggested that CHAC1 expression was also elevated in melanoma patients who responded to CTLA-4 blockade therapy (Supplementary Fig.”
CTLA4 blockade elicits paraneoplastic neurological disease in a mouse model
Yshii, L., Gebauer, C., Pignolet, B., Mauré, E., Queriault, C., Pierau, M., Saito, H., 昇, 鈴., Brunner-Weinzierl, M. C., Bauer, J., et al. (2016) · Brain · doi:10.1093/brain/aww225 · Cited by 127
“Downloaded from https://academic.oup.com/brain/article-abstract/139/11/2923/2422132 by guest on 31 December 2017 melanoma-specific CD8 + T cell responses against selfantigens and, possibly, against tumour neoantigens (Kvistborg et al., 2014; Van Allen et al., 2015).”
MethodGenetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration
Small, M., Treilleux, I., Couillault, C., Pissaloux, D., Picard, G., Paindavoine, S., Attignon, V., Wang, Q., Rogemond, V., Lay, S., et al. (2018) · Acta Neuropathologica · doi:10.1007/s00401-017-1802-y · Cited by 129
“These mutations might increase the immunogenicity of onconeural proteins by creating neoepitopes, which are now recognized as an important component of human tumor immunogenicity and have been associated with the therapeutic efficacy of inhibitory immune checkpoint (ICP) blockers [21, 41].”
BackgroundMpakali, A., & Stratikos, E. (2021) · Cancers · doi:10.3390/cancers13010134 · Cited by 137
Chae, Y. K., Davis, A. A., Raparia, K., Agte, S., Pan, A. P., Mohindra, N. A., Villaflor, V. M., & Giles, F. J. (2018) · Clinical Lung Cancer · doi:10.1016/j.cllc.2018.09.008 · Cited by 138
DUX4 Suppresses MHC Class I to Promote Cancer Immune Evasion and Resistance to Checkpoint Blockade
Chew, G.-L., Campbell, A. E., De Neef, E., Sutliff, N. A., Shadle, S. C., Tapscott, S. J., & Bradley, R. K. (2019) · Developmental Cell · doi:10.1016/j.devcel.2019.06.011 · Cited by 123
“…GSE78220; RRID: SCR_005012 RNA-seq data for Rickard et al., 2015 NCBI Sequence Read Archive SRP058319; RRID: SCR_004891 RNA-seq data for Van Allen et al., 2015 dbGaP phs000452.v2.p1; RRID: SCR_002709 RNA-seq data for Yasuda et al., 2016 Japanese Genotype-Phenotype Archive JGAS00000000047;…”
BackgroundMethodInfluentialNeoantigens and genome instability: impact on immunogenomic phenotypes and immunotherapy response
Mardis, E. R. (2019) · Genome Medicine · doi:10.1186/s13073-019-0684-0 · Cited by 123
KIT and Melanoma: Biological Insights and Clinical Implications
Pham, D. D. M., Guhan, S. M., & Tsao, H. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.7.562 · Cited by 136
Inhibition of estrogen signaling in myeloid cells increases tumor immunity in melanoma
Chakraborty, B., Byemerwa, J. K., Shepherd, J., Haines, C., Baldi, R., Gong, W., Liu, W., Mukherjee, D., Artham, S., Lim, F., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci151347 · Cited by 136
“patient’s response to ICB using published transcriptomic datasets from melanoma patients who 113 had received standard of care immune checkpoint blockade (32-34).”
BackgroundLandscape of Combination Immunotherapy and Targeted Therapy to Improve Cancer Management
Colli, L. M., Machiela, M. J., Zhang, H., Myers, T. A., Jessop, L., Delattre, O., Yu, K. F., & Chanock, S. J. (2017) · Cancer Research · doi:10.1158/0008-5472.can-16-3338 · Cited by 128
Computational Prediction and Validation of Tumor-Associated Neoantigens
Roudko, V., Greenbaum, B., & Bhardwaj, N. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00027 · Cited by 122
Autogene cevumeran with or without atezolizumab in advanced solid tumors: a phase 1 trial
Lopez, J. S., Powles, T. B., Braiteh, F., Siu, L. L., LoRusso, P. M., Friedman, C. F., Balmanoukian, A. S., Gordon, M. S., Yachnin, J., Rottey, S., et al. (2025) · Nature Medicine · doi:10.1038/s41591-024-03334-7 · Cited by 145
“The clinical efficacy of CPIs has been associated with promoting T cells directed against somatic cancer mutations 3–6 .”
Significance of Tumor Mutation Burden in Immune Infiltration and Prognosis in Cutaneous Melanoma
Kang, K., Xie, F., Mao, J., Bai, Y., & Wang, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.573141 · Cited by 163
“Studies have found that predicting the response to immunotherapy through the overall mutational load may serve as a new perspective (19, 20).”
BackgroundA High-Resolution Map of Human Enhancer RNA Loci Characterizes Super-enhancer Activities in Cancer
Chen, H., & Liang, H. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.08.020 · Cited by 137
CDKN2A Alterations and Response to Immunotherapy in Solid Tumors
Adib, E., Nassar, A. H., Akl, E. W., Alaiwi, S. A., Nuzzo, P. V., Mouhieddine, T. H., Sonpavde, G., Haddad, R. I., Mouw, K. W., Giannakis, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-0575 · Cited by 131
Self-citationChanging Technologies of RNA Sequencing and Their Applications in Clinical Oncology
Wang, Y., Mashock, M. J., Tong, Z., Mu, X., Chen, H., Zhou, X., Zhang, H., Zhao, G., Liu, B., & Li, X. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00447 · Cited by 142
“Recently, some other RNAseq-based signatures have been developed and validated, such as the diagnostic signature for thyroid cancer (15), prognostic signatures for both Neuroblastoma (16), and Lung Adenocarcinoma (17), and predictive signatures for metastatic melanoma (18, 19).”
BackgroundMultimodel preclinical platform predicts clinical response of melanoma to immunotherapy
Pérez-Guijarro, E., Yang, H. H., Araya, R. E., El Meskini, R., Michael, H. T., Vodnala, S. K., Marie, K. L., Smith, C., Chin, S., Lam, K. C., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0818-3 · Cited by 118
Targeting the immune microenvironment in acute myeloid leukemia: a focus on T cell immunity
Lamble, A. J., & Lind, E. F. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00213 · Cited by 119
DeFalco, J., Harbell, M. G., Manning-Bog, A., Baía, G. S., Scholz, A., Millare, B., Sumi, M., Zhang, D., Chu, F., Dowd, C., et al. (2017) · Clinical Immunology · doi:10.1016/j.clim.2017.10.002 · Cited by 124
ARID1A Mutations Are Associated with Increased Immune Activity in Gastrointestinal Cancer
Li, L., Li, M., Jiang, Z., & Wang, X. (2019) · Cells · doi:10.3390/cells8070678 · Cited by 126
Linxweiler, M., Kuo, F., Katabi, N., Lee, M., Nadeem, Z., Dalin, M. G., Makarov, V., Chowell, D., Doğan, S., Ganly, I., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-3758 · Cited by 120
“Recently, molecular features such as tumor mutational load (14, 15, 17, 26), clonal neoantigen load (27), HLA genotype (28, 29), immune infiltration into the tumor microenvironment (30), CD8þ T-cell activation (15, 31), and expression of immune checkpoint molecules (31, 32), have been correlated with response to immun…”
BackgroundPredictive biomarkers for response to immune checkpoint inhibition
Shum, B., Larkin, J., & Turajlic, S. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.036 · Cited by 131
A local human Vδ1 T cell population is associated with survival in nonsmall-cell lung cancer
Wu, Y., Biswas, D., Usaite, I., Angelova, M., Boeing, S., Karasaki, T., Veeriah, S., Czyzewska-Khan, J., Morton, C., Joseph, M., et al. (2022) · Nature Cancer · doi:10.1038/s43018-022-00376-z · Cited by 140
Chae, Y. K., Davis, A. A., Agte, S., Pan, A. P., Simon, N. I., Iams, W. T., Cruz, M. R. D. S., Tamragouri, K., Rhee, K., Mohindra, N. A., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0433 · Cited by 133
Yuan, Q., Deng, D., Chen, P., Ren, J., Wei, T., Wu, Z., Zhang, B., Li, S., Yin, P., & Shang, D. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.951137 · Cited by 127
Standardized Pathology Screening of Mature Tertiary Lymphoid Structures in Cancers
Vanhersecke, L., Bougoüin, A., Crombé, A., Brunet, M., Sofeu, C. L., Parrens, M., Pierron, H., Bonhomme, B., Lembege, N., Rey, C., et al. (2023) · Laboratory Investigation · doi:10.1016/j.labinv.2023.100063 · Cited by 133
Long, J., Lin, J., Wang, A., Wu, L., Zheng, Y., Yang, X., Wan, X., Xu, H., Chen, S., & Zhao, H. (2017) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0511-2 · Cited by 116
“A study of 110 melanoma patients treated with ipilimumab and analyzed by whole-exome sequencing showed that the neoantigen load served as predictive markers associated with the clinical benefit of ipilimumab [93].”
BackgroundFehlings, M., Simoni, Y., Penny, H. L., Becht, E., Loh, C. Y., Gubin, M. M., Ward, J. P., Wong, S. C., Schreiber, R. D., & Newell, E. W. (2017) · Nature Communications · doi:10.1038/s41467-017-00627-z · Cited by 115
Liu, W., Ruan, M., Wang, Y., Song, R., Ji, X., Xu, J., Dai, J., & Xue, W. (2018) · Small · doi:10.1002/smll.201801754 · Cited by 118
Yang, S. Y. C., Lien, S. C., Wang, B. X., Clouthier, D., Hanna, Y., Cirlan, I., Zhu, K., Bruce, J. P., Ghamrasni, S. E., Iafolla, M. A. J., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25432-7 · Cited by 125
Roszik, J., Haydu, L. E., Hess, K. R., Oba, J., Joon, A. Y., Siroy, A. E., Karpinets, T. V., Stingo, F. C., Baladandayuthapani, V., Tetzlaff, M. T., et al. (2016) · BMC Medicine · doi:10.1186/s12916-016-0705-4 · Cited by 115
“In addition, recent data from the melanoma and lung adenocarcinoma TCGAs showed a strong association between total tumor mutation load and immune cytolytic activity within samples, with an abrupt increase in the immune cytolytic activity within both tumor types beginning at approximately 100 total mutations within a t…”
BackgroundMethodInfluentialVokes, N. I., Liu, D., Ricciuti, B., Jimenez-Aguilar, E., Rizvi, H., Dietlein, F., He, M. X., Margolis, C. A., Elmarakeby, H. A., Girshman, J., et al. (2019) · JCO Precision Oncology · doi:10.1200/po.19.00171 · Cited by 114
Si, H., Kuziora, M., Quinn, K. J., Helman, E., Ye, J., Liu, F., Scheuring, U., Peters, S., Rizvi, N. A., Brohawn, P. Z., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3771 · Cited by 114
“Recent studies have shown that higher TMB may be predictive of better clinical benefit in melanoma (13, 14), non–small cell lung cancer (NSCLC; refs.”
BackgroundMonitoring immune responses in the tumor microenvironment
Wargo, J. A., Reddy, S. M., Reuben, A., & Sharma, P. (2016) · Current Opinion in Immunology · doi:10.1016/j.coi.2016.05.006 · Cited by 113
Muralidhar, S., Filia, A., Nsengimana, J., Poźniak, J., O'Shea, S. J., Diaz, J. M. S., Harland, M., Randerson‐Moor, J. A., Reichrath, J., Laye, J. P., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3927 · Cited by 121
Progress and Challenges in Precise Treatment of Tumors With PD-1/PD-L1 Blockade
Jiang, Y., Zhao, X., Fu, J., & Wang, H. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00339 · Cited by 124
BRAF inhibitors: resistance and the promise of combination treatments for melanoma
Griffin, M., Scotto, D., Josephs, D. H., Mele, S., Crescioli, S., Bax, H. J., Pellizzari, G., Wynne, M. D., Nakamura, M., Hoffmann, R. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.19836 · Cited by 130
“Mutational load, neoantigen load and cytolytic activity within the immune microenvironment correlate significantly with clinical benefit in patients with metastatic disease receiving ipilimumab [91].”
BackgroundPD-L1 expression in non-small cell lung cancer: correlations with genetic alterations
Scheel, A. H., Ansén, S., Schultheis, A. M., Scheffler, M., Fischer, R. N., Michels, S., Hellmich, M., George, J., Zander, T., Brockmann, M., et al. (2016) · OncoImmunology · doi:10.1080/2162402x.2015.1131379 · Cited by 111
“Besides the analysis of checkpoint proteins, genomic techniques to evaluate the mutational burden and neoantigens are rapidly evolving and might have superior predictive value for anti-PD-1 as well as for anti-CTLA4 therapy.(24,25) Comprehensive genomic approaches are still challenging, as they require sufficient tumo…”
BackgroundPersonalized Oncology Meets Immunology: The Path toward Precision Immunotherapy
Mandal, R., & Chan, T. A.-T. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0146 · Cited by 127
Griewank, K., Wiesner, T., Murali, R., Pischler, C., Müller, H., Koelsche, C., Möller, I., Franklin, C., Cosgarea, I., Sucker, A., et al. (2017) · Modern Pathology · doi:10.1038/modpathol.2017.146 · Cited by 118
Self-citationRegulation of Ovarian Cancer Prognosis by Immune Cells in the Tumor Microenvironment
Drakes, M. L., & Stiff, P. J. (2018) · Cancers · doi:10.3390/cancers10090302 · Cited by 119
“Tumor foreignness: for example, it is reported that the outcome to anti-CTLA-4 blockade therapy correlates with increased tumor mutational burden (a measure of neoantigen load) [169].”
BackgroundLoupakis, F., Depetris, I., Biason, P., Intini, R., Prete, A. A., Leone, F., Lombardi, P., Filippi, R., Spallanzani, A., Cascinu, S., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0611 · Cited by 111
“High TMB, defined as an increased total number of nonsynonymous mutations in the coding regions of genes, predicted benefit from ICI in “hot” tumors such as non-small cell lung cancer [6–8], melanoma [9, 10], unselected dMMR tumors [11], and bladder cancers [12].”
BackgroundProteome Instability Is a Therapeutic Vulnerability in Mismatch Repair-Deficient Cancer
McGrail, D. J., Garnett, J., Yin, J., Dai, H., Shih, D. J. H., Lam, T., Li, Y., Sun, C., Li, Y., Schmandt, R. E., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.01.011 · Cited by 120
Induction of neoantigen-reactive T cells from healthy donors
Ali, M., Földvári, Z., Giannakopoulou, E., Böschen, M.-L., Strønen, E., Yang, W., Toebes, M., Schubert, B., Kohlbacher, O., Schumacher, T. N., et al. (2019) · Nature Protocols · doi:10.1038/s41596-019-0170-6 · Cited by 119
Directing Traffic: How to Effectively Drive T Cells into Tumors
Anandappa, A. J., Wu, C. J., & Ott, P. A. (2020) · Cancer Discovery · doi:10.1158/2159-8290.cd-19-0790 · Cited by 152
Self-citationOsipov, A., Lim, S. J., Popović, A., Azad, N. S., Laheru, D. A., Zheng, L., Jaffee, E. M., Wang, H., & Yarchoan, M. M. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-0458 · Cited by 125
“Our results build upon the work of many other groups showing that TMB is associated with response and prolonged survival after treatment with ICI therapy (9, 10, 12, 16, 17).”
ResultOka, M., Xu, L., Suzuki, T., Yoshikawa, T., Sakamoto, H., Uemura, H., Yoshizawa, A. C., Suzuki, Y., Nakatsura, T., Ishihama, Y., et al. (2021) · Genome Biology · doi:10.1186/s13059-020-02240-8 · Cited by 108
Tang, B., Zhu, J., Zhao, Z., Lu, C., Liu, S., Fang, S., Zheng, L., Zhang, N., Chen, M., Xu, M., et al. (2021) · Journal of Advanced Research · doi:10.1016/j.jare.2021.01.018 · Cited by 116
Kong, Y., Xu, C., Cui, C., Yang, W., Yang, S., Chi, Z., Sheng, X., Si, L., Xie, Y., Yu, J., et al. (2021) · npj Genomic Medicine · doi:10.1038/s41525-021-00169-w · Cited by 133
Stenzinger, A., Endris, V., Budczies, J., Merkelbach‐Bruse, S., Kazdal, D. N., Dietmaier, W., Pfarr, N., Siebolts, U., Hummel, M., Herold, S., et al. (2020) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.01.023 · Cited by 119
MHC-I genotype and tumor mutational burden predict response to immunotherapy
Goodman, A. M., Castro, A., Pyke, R. M., Okamura, R., Kato, S., Riviere, P., Frampton, G., Sokol, E., Zhang, X., Ball, E. D., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00743-4 · Cited by 109
Wang, G., Xu, D., Zhang, Z., Li, X., Shi, J., Sun, J., Li, X., Li, X., Zhou, M., & Zheng, T. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00200-4 · Cited by 131
Coulton, A., Murai, J., Qian, D., Thakkar, K., Lewis, C. E., & Litchfield, K. (2024) · Nature Communications · doi:10.1038/s41467-024-49885-8 · Cited by 135
“This expanded cohort consists of 1446 ICI-treated patients from fi ve cancer types, 552 bladder cancer, 411 lung cancer, 226 melanomas, 212 renal carcinomas and 45 gastric cancers 115 – 124 .”
Wistuba-Hamprecht, K., Martens, A., Heubach, F., Romano, E., Geukes Foppen, M., Yuan, J., Postow, M., Wong, P., Mallardo, D., Schilling, B., et al. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2016.12.011 · Cited by 108
“Several recent studies highlight the role of T-cell responses targeting neo-epitopes for a favourable clinical response to ipilimumab [38,45,46].”
Self-citationMadore, J., Strbenac, D., Vilain, R., Menzies, A. M., Yang, J. Y. H., Thompson, J. F., Long, G. V., Mann, G. J., Scolyer, R. A., & Wilmott, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1714 · Cited by 108
“Antitumor immunity has alsobeen linked tohighermutation levels in cancer implicating neoantigens in affecting T-cell responses (39) and responses to both CTLA4 and PD-L1 therapies have been demonstrated to have a genetic basis largely dependent on the presence of specific types of patient neoantigens (33, 40, 41).”
BackgroundMechanisms of Tumor Cell–Intrinsic Immune Evasion
Spranger, S., & Gajewski, T. F. (2018) · Annual Review of Cancer Biology · doi:10.1146/annurev-cancerbio-030617-050606 · Cited by 108
“The tumor microenvironment is characterized by a variety of metabolic changes, including the induction of a hypoxic environment mostly mediated through rapid proliferation and inadequate angiogenesis (Vander Heiden et al. 2009).”
BackgroundMethodResultInfluentialKoeppel, F., Blanchard, S., Jovelet, C., Génin, B., Marcaillou, C., Martin, E., Rouleau, É., Solary, É., Soria, J., André, F., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0188174 · Cited by 116
Peters, S., Reck, M., Smit, E. F., Mok, T. S. K., & Hellmann, M. D. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz109 · Cited by 116
Pan-cancer analysis of SETD2 mutation and its association with the efficacy of immunotherapy
Lu, M., Zhao, B., Liu, M., Wu, L., Li, Y., Zhai, Y., & Shen, X. (2021) · npj Precision Oncology · doi:10.1038/s41698-021-00193-0 · Cited by 123
Cancer cell-intrinsic mechanisms driving acquired immune tolerance
Ghorani, E., Swanton, C., & Quezada, S. A. (2023) · Immunity · doi:10.1016/j.immuni.2023.09.004 · Cited by 125
“147,148 149–155 In general, cancer genomic and clonal diversification resulting in tumor heterogeneity 156 occurs through mechanisms 157 including defective DNA damage repair, 158 replication stress, 159 APOBEC3 enzyme expression, 160,161 and epigenetic dysregulation.”
BackgroundNeoantigen prediction and the need for validation
Vitiello, A., & Zanetti, M. (2017) · Nature Biotechnology · doi:10.1038/nbt.3932 · Cited by 126
Lin, Z., Huang, L., Li, S., Gu, J., Cui, X., & Zhou, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-78560-3 · Cited by 119
Dobosz, P., Stępień, M., Golke, A., & Dzieciątkowski, T. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052847 · Cited by 131
Metadata
- Authors
- Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., Utikal, J., Hassel, J. C., Weide, B., Kaehler, K. C., Loquai, C., Mohr, P., Gutzmer, R., Dummer, R., Gabriel, S., Wu, C. J., Schadendorf, D., & Garraway, L. A.
- Affiliations
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
- Broad Institute (US)
- Deutsches Konsortium für Translationale Krebsforschung (DE)
- The Netherlands Cancer Institute (NL)
- Department of Medical Oncology, Netherlands Cancer Institute, 1066 CX Amsterdam, Netherlands.
- University Hospital Zurich (CH)
- German Cancer Research Center (DE)
- Heidelberg University (DE)
- Universitätsklinikum Tübingen (DE)
- University Hospital Schleswig-Holstein (DE)
- University Medical Center of the Johannes Gutenberg University Mainz (DE)
- Elbe Kliniken Stade-Buxtehude (DE)
- Medizinische Hochschule Hannover (DE)
- Corresponding author
- Miao, Diana
- Schilling, Bastian
- Schadendorf, Dirk
- Garraway, Levi A.
- ORCID
- Venue
- Science
- Published
- 2015-10-09
- Volume
- 350
- Issue
- 6257
- Pages
- 207-211
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC5054517
- OpenAlex
- W2107429737
- Cited by
- 2,839
- References
- 42
- Citations by year
- 2026: 106 · 2025: 187 · 2024: 236 · 2023: 308 · 2022: 313 · 2021: 348 · 2020: 327 · 2019: 274 · 2018: 270 · 2017: 248 · 2016: 207 · 2015: 12
- FWCI
- 107.45
- Type
- journal article
- Language
- en
- Update notices
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion)
- Funders
- NIH (U54 HG003067)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- metastatic melanoma, CTLA-4 blockade, ipilimumab, immune checkpoint inhibitors, tumor mutational burden, neoantigens, tumor microenvironment, predictive biomarkers, treatment response, exome sequencing, transcriptome, germline mutations
- MeSH terms
- Ipilimumab, Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antigens, Neoplasm, DNA Mutational Analysis, Female, HLA Antigens, Humans, Male, Melanoma, Middle Aged, Mutation, Skin Neoplasms, Cohort Studies, Drug Resistance, Neoplasm, Genomics, Biomarkers, Pharmacological, Young Adult, Tumor Microenvironment, Cell Cycle Checkpoints, Exome, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.